PLASMA EXCHANGE FOR TRANSPLANTATION-ASSOCIATED THROMBOTIC MICROANGIOPATHY IN STEM CELL TRANSPLANTATION FROM AN HLA-MISMATCHED FAMILY DONOR

DOI Web Site 17 References Open Access
  • Kitagawa Junichi
    Department of Transfusion Medicine, Gifu Municipal Hospital Department of Hematology, Gifu Municipal Hospital
  • Fukunaga Keiko
    Department of Hematology, Hyogo Medical University Hospital
  • Oshima Yumi
    Department of Transfusion Medicine, Gifu Municipal Hospital Department of Pediatrics, Gifu Municipal Hospital
  • Kinoshita Seijiro
    Department of Transfusion Medicine, Gifu Municipal Hospital
  • Watanabe Takanori
    Department of Transfusion Medicine, Gifu Municipal Hospital
  • Usuda Naomi
    Department of Transfusion Medicine, Gifu Municipal Hospital
  • Kasahara Senji
    Department of Hematology, Gifu Municipal Hospital
  • Ikemoto Junko
    Department of Transfusion Medicine and Cell Therapy, Hyogo Medical University Hospital
  • Ikegame Kazuhiro
    Department of Hematology, Hyogo Medical University Hospital

Bibliographic Information

Other Title
  • 血縁者間HLA不適合造血幹細胞移植関連血栓性微小血管症に対する血漿交換療法

Search this article

Description

<p>Objective: HLA-mismatched stem cell transplantation (SCT) from a family donor using steroids for graft-versus-host disease (GVHD) prophylaxis is useful in refractory hematological diseases, but is associated with many complications. The purpose of this study was to investigate the efficacy of plasma exchange (PE) therapy for transplantation-associated thrombotic microangiopathy (TA-TMA) in patients with HLA-mismatched SCT. Methods: Between October 2016 and September 2021, we retrospectively evaluated 22 patients who developed TA-TMA and received PE after HLA-mismatched SCT from a family donor. Results: Median age was 36 years. Twenty-one patients were in a state of non-remission, and 4 patients had a 2-HLA-haplotype mismatched family donor. For GVHD prophylaxis, tacrolimus plus methylprednisolone was administered to all patients. PE was effective in 15 patients (68.2%), and duration from the onset of TA-TMA to PE initiation was slightly shorter in these cases. Three patients developed heart failure during PE, although this was reversible. The 100-day and 1-year survival rates were 50.0% and 9.1%, respectively. Conclusion: PE may be effective and safe for TA-TMA after allogeneic HLA-mismatched SCT.</p>

Journal

References(17)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top